ICU Medical, Inc. (NASDAQ:ICUI) Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC decreased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 1.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,411,638 shares of the medical instruments supplier’s stock after selling 31,967 shares during the quarter. Janus Henderson Group PLC owned 9.85% of ICU Medical worth $439,449,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ICUI. Allworth Financial LP grew its position in ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 100 shares during the period. Xponance Inc. grew its position in shares of ICU Medical by 6.0% during the 2nd quarter. Xponance Inc. now owns 1,977 shares of the medical instruments supplier’s stock valued at $235,000 after acquiring an additional 112 shares during the period. Equitable Trust Co. increased its stake in shares of ICU Medical by 2.2% in the 3rd quarter. Equitable Trust Co. now owns 5,213 shares of the medical instruments supplier’s stock valued at $950,000 after purchasing an additional 112 shares in the last quarter. CWM LLC raised its holdings in ICU Medical by 18.5% in the 2nd quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock worth $91,000 after purchasing an additional 120 shares during the period. Finally, Hexagon Capital Partners LLC boosted its position in ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Price Performance

NASDAQ:ICUI opened at $160.96 on Tuesday. ICU Medical, Inc. has a twelve month low of $83.26 and a twelve month high of $196.26. The company’s 50-day moving average price is $174.60 and its 200-day moving average price is $147.67. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, COO Christian B. Voigtlander sold 1,962 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $169.08, for a total value of $331,734.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Friday, November 1st. The stock was sold at an average price of $171.84, for a total value of $2,062,080.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,973,261.12. This represents a 10.29 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,364 shares of company stock worth $6,869,878. Insiders own 6.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ICUI shares. Jefferies Financial Group began coverage on ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 target price for the company. Raymond James increased their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp upped their price target on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. Finally, StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.